High-grade non-Hodgkin's lymphoma stage I: A retrospective study of treatment, outcome and prognostic factors in 213 patients

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 171-177

  Osterman, Birgitta ^a   Cavallin Ståhl, Eva ^b   Hagberg, Hans ^c   Linden, Ola ^b   Lenner, Per ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, HIGH-GRADE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0029885997     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098498     Document Type: Article

References (40)

1. Jones SE, Fuks Z, Kaplan HS, Rosenberg SA. Non-Hodgkin's lymphomas. V. Results of radiotherapy. Cancer 1973; 32; 682-91.
2. van Unnik JAM, Breur K, Burgers JMV, et al. Non-Hodgkin's lymphomata: Clinical features in relation to histology. Br J Cancer 1975; 31 (Suppl. 2): 201-7.
3. Peckham MH, Guay JP, Hamlin IME, Lukes RJ. Survival in localized nodal and extranodal non-Hodgkin's lymphomata. Br J Cancer 1975; 31 (Suppl 2): 413-24.
4. Bitran JD, Kinzie J, Sweet DL, et al. Survival of patients with localized histiocytic lymphoma. Cancer 1977; 39: 342-6.
5. Chen MG, Prosnitz LR, Gonzales-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 1979; 43: 1245-54.
6. Levitt SH, Bloomfield CD, Frizzera G, Chung KK Lee. Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep 1980; 64: 175-7.
7. Sweet DL, Kinzie J, Gaeke MA, Golomb HM, Feurgesson TL, Ultman JE. Survival of patients with localized histiocytic lymphoma. Blood 1981; 58: 1218.
8. Hagberg H, Pettersson U, Glimelius B, Sundström C. Prognostic factors in non-Hodgkin lymphoma stage I treated with radiotherapy. Acta Oncol 1989; 28: 45-50.
9. Kaminski MS, Coleman CN, Colby TV. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiotherapy. Ann Intern Med 1986; 104: 747-56.
10. Hudson BV, Hudson GV, MacLennan KA, Anderson L, Linch DC. Clinical stage I non-Hodgkin's lymphoma: long term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 1088-93.
11. Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavourable histology. Blood 1983; 62: 413-8.
12. Cabanillas F. Chemotherapy as definite treatment of stage I-II large cell and diffuse mixed lymphomas. Hematol Oncol 1985; 3: 25-31.
13. Mauch P, Leonard R, Skarin A, et al. Improved survival following combined radiation therapy and chemotherapy for unfavourable prognosis stage I-II non-Hodgkin's lymphoma. J Clin Oncol 1985; 3: 1301-8.
14. Bajetta E, Valagussa P, Bonadonna G, et al. Combined modality treatment for stage I II lymphomas: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys 1988; 15: 3-12.
15. Horwich A, Catton CN, Quigley M, Easton D, Brada M. The management of early-stage aggressive non-Hodgkin's lymphoma. Hematol Oncol 1988; 6: 291-8.
16. Richards MA, Gregory WM, Hall PA, et al. Management of localized non-Hodgkin's lymphoma: The experience at St. Bartholomew's hospital 1972-1985. Hematol Oncol 1989; 7: 1-18.
17. Jones SE, Miller T, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989; 7: 1186-91.
18. Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized agressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 7: 1295-302.
19. Nussbaum H, Koo C, Kagan AR, Aroor R, Ryoo CM. Large cell lymphoma stage IA/IAE. Ann J Clin Oncol (CCT) 1991; 14: 195-9.
20. Tondini CT, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggress-ive non-Hodgkin's lymphomas. J Clin Oncol 1993; 11: 720-5.
21. Coiffier B, Lepage E. Prognosis of aggressive lymphomas: A study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558-64.
22. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211-9.
23. Hoskins PJ, Ng V, Spinelli JJ, Klimo P, Connors JM. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220-6.
24. Osterman B, Jonsson H, Tavelin B, Lenner P. Non-Hodgkin's lymphoma in Northern Sweden. Prognostic factors and response to treatment. Acta Oncol 1993; 32: 507-15.
25. Osterman B, Dige U, Roos G, Jonsson H, Lenner P. Non-Hodgkin's lymphoma in Northern Sweden. A retrospective analysis of morphologic diagnosis and stage in a material from the Swedish Cancer Registry. Acta Oncol 1993; 32: 393-8.
26. Fine HA, Meyer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093-104.
27. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the comittee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1.
28. Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld G, van Unnik JAM. Classification of non-Hodgkin's lymphomas. Lancet 1974; 2: 406-8.
29. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-3.
30. Connors JM, Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions; 1987 update and additional observations. Semin Hematol 1988; 25 (Suppl 2): 41-6.
31. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
32. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
33. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38: 933-42.
34. Cox DR. Regression model and life table. J R Stat Soc Series B 1972; 34; 1412-9.
35. Longo DL. Combined modality therapy for localized agressive lymphoma: Enough or too much? J Clin Oncol 1989; 7: 1179-81.
36. Solal-Celingy P, Chastang C, Herrera A, et al. Age as the main prognostic factor in adult aggessive non-Hodgkin's lymphoma. Am J Med 1987; 83: 1975-9.
37. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269-73.
38. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
39. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-44.
40. Schneider RJ, Seibert K, Passe S, et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer 1980; 46: 139-43.